FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320033054> ?p ?o ?g. }

• W4320033054 endingPage "119" @default.
• W4320033054 startingPage "115" @default.
• W4320033054 abstract "To analyze the relationship between microRNA (miR)-21, miR-191 and clinical stage of patients with diffuse large B-cell lymphoma (DLBCL).100 patients with DLBCL treated in Shanxi Fenyang Hospital from January 2019 to January 2021 were selected as the research subjects. All patients was divided into stage I, stage II, stage III and stage IV according to Ann-Arbor (Cotswolds) staging system at admission. The baseline data of patients at different clinical stages were counted and compared in detail. The relationship between the levels of miR-21 and miR-191 and the clinical stage of DLBCL patients was mainly analyzed.Among the 100 patients with DLBCL, there were 15 patients at stage I, 25 patients at stage II, 37 patients at stage III and 23 patients at stage IV. The levels of miR-21 and miR-191 in patients at stage Ⅰ, Ⅱ, Ⅲ and Ⅳ were increased gradually, which showed statistically significant differences (P<0.05). According to Kendall's tau-b correlation analysis, it was found that the levels of miR-21 and miR-191 were positively correlated with the clinical stage of DLBCL patients (r=0.566, 0.636). Multiple logistic regression analysis showed that the overexpression of serum miR-21 and miR-191 was a risk factor for high clinical stage in patients with DLBCL (OR>1, P<0.05). Bivariate Pearson correlation analysis showed that there was a positive correlation between miR-21 and miR-191 levels in patients with DLBCL (r=0.339).The overexpression of miR-21 and miR-191 in patients with DLBCL is related to high clinical stage.miR-21、miR-191与弥漫性大B细胞淋巴瘤患者 临床分期的相关性.分析微小核糖核酸（miR）-21、miR-191与弥漫性大B细胞淋巴瘤（DLBCL）患者临床分期的关系.选取2016年1月-2021年1月山西省汾阳医院收治的100例DLBCL患者作为研究对象，于入院时根据Ann-Arbor（Cotswolds)分期将所有患者的临床分期分为Ⅰ期、Ⅱ期、Ⅲ期、Ⅳ期；详细统计并比较不同临床分期患者的基线资料，重点分析miR-21、miR-191水平与DLBCL患者临床分期的关系.100例DLBCL患者中临床分期Ⅰ期15例，Ⅱ期25例，Ⅲ期37例，Ⅳ期23例。Ⅰ期、Ⅱ期、Ⅲ期和Ⅳ期患者的miR-21、miR-191水平依次升高，差异有统计学意义（P<0.05）。经Kendall's tau-b相关性分析发现，miR-21、miR-191水平与DLBCL患者临床分期呈正相关（r=0.566、0.636）；多项Logistic回归分析结果显示，血清miR-21、miR-191过表达是DLBCL患者临床高分期的危险因子（OR>1，P<0.05）；双变量Pearson相关性分析结果显示，DLBCL患者miR-21水平与miR-191水平之间呈正相关（r=0.339）.DLBCL患者的miR-21、miR-191过表达与临床高分期有关." @default.
• W4320033054 created "2023-02-12" @default.
• W4320033054 creator A5032318211 @default.
• W4320033054 creator A5060248930 @default.
• W4320033054 creator A5072919064 @default.
• W4320033054 creator A5089079624 @default.
• W4320033054 date "2023-02-01" @default.
• W4320033054 modified "2023-10-04" @default.
• W4320033054 title "[Correlation between miR-21, miR-191 and Clinical Stage of Patients with Diffuse Large B-Cell Lymphoma]." @default.
• W4320033054 doi "https://doi.org/10.19746/j.cnki.issn.1009-2137.2023.01.018" @default.
• W4320033054 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36765486" @default.
• W4320033054 hasPublicationYear "2023" @default.
• W4320033054 type Work @default.
• W4320033054 citedByCount "0" @default.
• W4320033054 crossrefType "journal-article" @default.
• W4320033054 hasAuthorship W4320033054A5032318211 @default.
• W4320033054 hasAuthorship W4320033054A5060248930 @default.
• W4320033054 hasAuthorship W4320033054A5072919064 @default.
• W4320033054 hasAuthorship W4320033054A5089079624 @default.
• W4320033054 hasConcept C117220453 @default.
• W4320033054 hasConcept C126322002 @default.
• W4320033054 hasConcept C143998085 @default.
• W4320033054 hasConcept C146357865 @default.
• W4320033054 hasConcept C151730666 @default.
• W4320033054 hasConcept C151956035 @default.
• W4320033054 hasConcept C2524010 @default.
• W4320033054 hasConcept C2778559949 @default.
• W4320033054 hasConcept C2779338263 @default.
• W4320033054 hasConcept C2779714933 @default.
• W4320033054 hasConcept C33923547 @default.
• W4320033054 hasConcept C71924100 @default.
• W4320033054 hasConcept C86803240 @default.
• W4320033054 hasConcept C90924648 @default.
• W4320033054 hasConceptScore W4320033054C117220453 @default.
• W4320033054 hasConceptScore W4320033054C126322002 @default.
• W4320033054 hasConceptScore W4320033054C143998085 @default.
• W4320033054 hasConceptScore W4320033054C146357865 @default.
• W4320033054 hasConceptScore W4320033054C151730666 @default.
• W4320033054 hasConceptScore W4320033054C151956035 @default.
• W4320033054 hasConceptScore W4320033054C2524010 @default.
• W4320033054 hasConceptScore W4320033054C2778559949 @default.
• W4320033054 hasConceptScore W4320033054C2779338263 @default.
• W4320033054 hasConceptScore W4320033054C2779714933 @default.
• W4320033054 hasConceptScore W4320033054C33923547 @default.
• W4320033054 hasConceptScore W4320033054C71924100 @default.
• W4320033054 hasConceptScore W4320033054C86803240 @default.
• W4320033054 hasConceptScore W4320033054C90924648 @default.
• W4320033054 hasIssue "1" @default.
• W4320033054 hasLocation W43200330541 @default.
• W4320033054 hasOpenAccess W4320033054 @default.
• W4320033054 hasPrimaryLocation W43200330541 @default.
• W4320033054 hasRelatedWork W1987289536 @default.
• W4320033054 hasRelatedWork W2032099400 @default.
• W4320033054 hasRelatedWork W2165570306 @default.
• W4320033054 hasRelatedWork W2283115812 @default.
• W4320033054 hasRelatedWork W2287791769 @default.
• W4320033054 hasRelatedWork W2359617613 @default.
• W4320033054 hasRelatedWork W2394693432 @default.
• W4320033054 hasRelatedWork W3029471422 @default.
• W4320033054 hasRelatedWork W3096138557 @default.
• W4320033054 hasRelatedWork W3115337401 @default.
• W4320033054 hasVolume "31" @default.
• W4320033054 isParatext "false" @default.
• W4320033054 isRetracted "false" @default.
• W4320033054 workType "article" @default.